Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.
about
From BILAG to BILAG-based combined lupus assessment-30 years onUrinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritisEndpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosusToward the development of criteria for global flares in juvenile systemic lupus erythematosusNeutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity.Pattern of systemic lupus erythematosus in Egyptian patients: the impact of disease activity on the quality of lifeClassification criteria for systemic lupus erythematosus: a review.Disease activity assessment in SLE: do we have the right instruments?Belimumab in systemic lupus erythematosus: an update for clinicians.A review of health related quality of life in systemic lupus erythematosus.Novel evidence-based systemic lupus erythematosus responder index.Measuring outcomes in systemic lupus erythematosus clinical trials.Top 10 things to know about lupus activity measures.Validation of the medical outcomes study family and marital functioning measures in SLE patients in Singapore.A damage index for lupus patients--where are we now?Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus.Systemic lupus erythematosus: clinical manifestations, treatment and economics.Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy.Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients.Quality of life and economic evaluation in SLE clinical trials.A Chinese version of the Rheumatology Attitudes Index is a valid and reliable measure of learned helplessness in patients with SLE.Validation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosus.The rating scale preference measure as an evaluative measure in systemic lupus erythematosus.
P2860
Q28081809-B3A1A4C2-0A46-4D74-B8F7-6B69D985FE23Q33785628-0ACD0A52-884A-4D11-AE28-F24AEF2E64D7Q33957431-45897785-03D2-4648-A35D-8B14C4B79AD0Q34046983-5B8316A6-0FAD-42A2-A574-ED598685D0FCQ34157817-B2E61DAA-5759-407A-A701-1ECDFD93CAA6Q34626276-3F0CA712-60C4-4CD3-AA19-AA43648DED4EQ34720014-E2806C15-6EDA-4606-A005-303620FA294BQ35062019-2A48EC0B-CECC-43DD-96B4-84E7E9DA3216Q35973810-C46E8E50-56BE-4091-9B4F-DC7E1E683EE8Q36171764-E7B3161E-6A74-497D-AC20-81CCBD86132CQ36443781-45B5EB3E-FB02-49BC-B818-0B990A2FFBEFQ36660670-B4CB5C03-E083-47E9-9A1E-8FD6A61D4E0AQ37356378-A37667D8-C345-4A72-AE8E-D45934A59BE5Q37914899-1B513866-3B06-41C1-8060-33B0D1A3C9AFQ38100735-2482EBF9-D4AF-4BFC-AD5E-7644AD8D09A4Q39517497-1F3D57FC-F586-4F34-93C5-983FF701DA10Q43582073-F2EF48C0-D958-4171-A541-CE43E0ACDAF0Q46374758-ED4DA14C-61DB-4290-89F9-457BBF4F9A47Q46686656-F97522EE-E74D-4CE5-B5DC-99691A071979Q48792788-3E4D8216-EC85-4C48-B9B0-82C40C72BDDFQ50579897-726B6294-C37C-48FE-9E88-2D96F6304E2FQ51084575-87879E56-41CF-4BD7-9F85-D4D508C928D7Q52121169-F76D6EE6-FCD0-4AFD-9223-3D9EB543C835Q53497193-53D4FB93-06D3-4A02-B27A-AA5AAC000503Q53497194-5AA600EA-99DB-4B7D-9D5E-240088A37542
P2860
Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Further validation of the BILA ...... systemic lupus erythematosus.
@ast
Further validation of the BILA ...... systemic lupus erythematosus.
@en
Further validation of the BILA ...... systemic lupus erythematosus.
@nl
type
label
Further validation of the BILA ...... systemic lupus erythematosus.
@ast
Further validation of the BILA ...... systemic lupus erythematosus.
@en
Further validation of the BILA ...... systemic lupus erythematosus.
@nl
prefLabel
Further validation of the BILA ...... systemic lupus erythematosus.
@ast
Further validation of the BILA ...... systemic lupus erythematosus.
@en
Further validation of the BILA ...... systemic lupus erythematosus.
@nl
P2093
P2860
P356
P1476
Further validation of the BILA ...... systemic lupus erythematosus.
@en
P2093
P2860
P304
P356
10.1136/ARD.55.10.756
P407
P577
1996-10-01T00:00:00Z